Biotech.
Company
- Reports this week
- 0
- Active events
- 1
- Connections
- 59
What's happening
Active this week
Earlier this month
-
A biotech initiative plans to expand to multiple cities, drawing on past biotech career experience.Some support1 report
-
Royalty Pharma is investing in drug makers and developers to diversify its portfolio in the biotech sector.Some support1 report
-
Policymakers are considering ways to influence the drug market, including potential changes to patent rights and the FDA approval process.Some support3 reports1 development inside
-
The biotech industry is set to develop new plastics and fuels, and Google AI is predicting future population trends.Some support1 report
-
Experts observed AI skepticism and measured efficiency in Bangladeshi factories, urging governments to close foundational gaps.Some support1 report
One to three months ago
Gone quiet
No new reports in 90+ days-
Amgen is classified as biotech for legacy reasons, a classification influenced by past failures experienced in London.Some support1 report
-
The SEC legally requires fiduciaries to prioritize client interests, while specific ETFs like XBI offer equal-weighted exposure to biotech and hedge against AI concentration risk.Some support2 reports
-
M&A activity is driving sector recovery.Some support1 report1 development inside
-
Structure Therapeutics is an early-stage business operating within the biotech sector.Speculative1 report
-
Gains in Big Tech shares fueled market rise, while biotech company Enveda reached a billion-dollar valuation and a new international equity ETF was launched.Some support1 report
-
EIT Food is discussing the shift towards biotech-driven approaches to address climate change impacts on Arabica coffee yields.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Biotech
Events traced to Biotech, step by step, newest firstAround Biotech this week
News at the entities that move Biotech most-
FDA StructuralFDA approved a drug based on UVA research led by Xuemei Huang.Moves Biotech
-
Federal Trade Commission StructuralThe Federal Trade Commission filed a complaint against Amway, involving Washington.Moves Biotech
-
Massachusetts StructuralJames Arciero serves as a state representative in Massachusetts.Moves Biotech
-
Scott Bessent StructuralScott Bessent, US Treasury Secretary, called for balanced trade ties between the US and China.Moves Biotech
-
Royalty Pharma StructuralFDA granted approvals for RASONQUE and WELTRUZA on November 4, 2026.Moves Biotech
-
Goldman Sachs Mentioned togetherSponsors toned down valuations after huddles, citing concerns over over-bureaucratic UK governance rules.Moves Biotech
Connections
The 32 strongest of 59, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA functions as the essential regulatory gatekeeper whose approvals and delays dictate the market viability of biotech companies.
-
Martin Shkreli Operational
Martin Shkreli actively trades and comments on biotech stocks.
-
Christian Freitag Structural
Biotech appointed Christian Freitag as Chief Medical Officer.
-
State Street Operational
State Street provides management services for exchange-traded funds focused on the biotech sector.
-
Federal Trade Commission Structural
The Federal Trade Commission regulates the biotech industry regarding drug industry violations.
-
EIT Food Structural
one depends on the other
-
ICON plc Operational
Both companies operate within the same Pharma/Biotech market segment, indicating active market interaction and potential competition.
-
Royalty Pharma Structural
Royalty Pharma invests in drug makers and developers, providing financial support to the Biotech sector.
Show all 32 connections
-
Massachusetts Structural
Massachusetts state tax laws structurally impact the R&D incentives of biotech companies.
-
Vertex Pharmaceuticals Shared context
Vertex Pharmaceuticals is identified as a major holding within the broader biotech sector ETF.
-
Goldman Sachs Mentioned together
Goldman Sachs provides analysis and commentary on the performance and valuation of the Biotech sector.
-
ImmunityBio Shared context
ImmunityBio's performance is described as being tied to the overall performance of the Biotech sector.
-
MarketBeat Mentioned together
MarketBeat features Biotech stocks using its stock screener tool.
-
Sarepta Shared context
Sarepta operates within the Biotech sector, and its performance is observed relative to the sector's market conditions.
-
AbbVie Shared context
AbbVie is categorized as a company operating within the Biotech sector.
-
Moderna Shared context
Moderna is identified as a company operating within the Biotech sector.
-
Congress Structural
Biotech is subject to formal regulation by Congress, which is considering changes to patent rights.
-
Amgen Mentioned together
Amgen is classified and listed within the broader Biotech sector.
-
Incyte Mentioned together
Biotech is mentioned in the M&A context of Incyte.
-
Gilead Sciences Mentioned together
Gilead Sciences is cited as a member of the Biotech sector.
-
Regeneron Pharmaceuticals Mentioned together
Regeneron Pharmaceuticals is categorized as a biotech company and listed among biotech stocks.
-
Scott Bessent Structural
Scott Bessent sought to include the biotech sector in targeted policy areas.
-
Nasdaq Shared context
Biotech companies operate within the market structure provided by Nasdaq, which serves as a major listing exchange.
-
Halozyme Therapeutics Mentioned together
Halozyme Therapeutics is classified as a biopharma technology platform company, placing it within the broader biotech sector.
-
Oceanside Shared context
Biotech is associated with Oceanside, suggesting the company has operated or held a career connection in the location.
-
Natera Shared context
Natera is identified as a diagnostics company operating within the biotech sector.
-
London Shared context
Past failures in London influenced the sector prejudice of the Biotech industry.
-
Bangladesh Mentioned together
The relationship is observed in the context of general industry skepticism regarding AI.
-
Sioux Falls Mentioned together
The provided evidence does not contain any information linking Biotech to Sioux Falls.
-
Arabica Mentioned together
no direct coupling
-
FED Mentioned together
The provided evidence focuses solely on the FED's response to inflation and tariffs, showing no direct coupling or relationship with Biotech.
-
Barry Callebaut Mentioned together
The evidence establishes that companies like Barry Callebaut are attracted to cultivated coffee, but does not define a specific relationship between Biotech and Barry Callebaut.
History
Events by the month they beganNovember 2026
2 eventsOctober 2026
3 events- Royalty Pharma is investing in drug makers and developers to diversify its portfolio in the biotech sector.
- The biotech industry is set to develop new plastics and fuels, and Google AI is predicting future population trends.
- Experts observed AI skepticism and measured efficiency in Bangladeshi factories, urging governments to close foundational gaps.
August 2026
1 eventShow 2 earlier months
July 2026
3 events- The biotech sector relies on market infrastructure for raising capital.
- Amgen is classified as biotech for legacy reasons, a classification influenced by past failures experienced in London.
- The SEC legally requires fiduciaries to prioritize client interests, while specific ETFs like XBI offer equal-weighted exposure to biotech and hedge against AI concentration risk.
June 2026
4 events- M&A activity is driving sector recovery.
- Structure Therapeutics is an early-stage business operating within the biotech sector.
- Gains in Big Tech shares fueled market rise, while biotech company Enveda reached a billion-dollar valuation and a new international equity ETF was launched.
- EIT Food is discussing the shift towards biotech-driven approaches to address climate change impacts on Arabica coffee yields.